Amlodipine
- Generic Name
- Amlodipine
- Brand Names
- Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25ClN2O5
- CAS Number
- 88150-42-9
- Unique Ingredient Identifier
- 1J444QC288
- Background
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnorma...
- Indication
Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :
• Hypertension
• Coronary artery disease
• Chronic stable angina
• Vasospastic angina (Prinzmetal’s or Variant angina)
...
- Associated Conditions
- Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina
- Associated Therapies
- -
Comparison of Optimal Hypertension Regimens
- Conditions
- Interventions
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2021-07-28
- Target Recruit Count
- 1320
- Registration Number
- NCT02847338
- Locations
- 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom
🇬🇧University Hospital Llandough, Cardiff, United Kingdom
🇬🇧Queen Elizabeth Hospital, Birmingham, United Kingdom
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 37
- Registration Number
- NCT02834403
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
DP-R212 Pharmacokinetic Study Phase I
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Alvogen Korea
- Target Recruit Count
- 36
- Registration Number
- NCT02814500
DP-R212 Pharmacokinetic Study
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Alvogen Korea
- Target Recruit Count
- 38
- Registration Number
- NCT02789475
- Locations
- 🇰🇷
Inha university hospital, Jung-gu, Incheon, Korea, Republic of
N-of-1 Trials for Blood Pressure Medications in Adults
- Conditions
- Interventions
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 10
- Registration Number
- NCT02744456
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2018-07-12
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 40
- Registration Number
- NCT02671695
- Locations
- 🇪🇬
Faculty of Medicine- Tanta University, Tanta, Gharbia, Egypt
Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 135
- Registration Number
- NCT02651870
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus
- Conditions
- Interventions
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 49
- Registration Number
- NCT02644395
- Locations
- 🇳🇱
ErasmusMC, Rotterdam, Netherlands
CKD-330 Phase 3 Trial in Amlodipine Non-responder
- Conditions
- Interventions
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 160
- Registration Number
- NCT02586311
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs
- Conditions
- Interventions
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 53
- Registration Number
- NCT02548286
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.